Dragon Announces Results of the Annual General Meeting

News

Dragon Pharmaceutical Inc. (OTC BB: DRUG; TSX: DDD) (“the Company”) is pleased to announce the results of the Annual Shareholders?Meeting held on August 12, 2005.

There were 54,818,706 shares equaling 87.20% of the outstanding shares represented at this meeting. All of the following proposals were approved by a substantial majority of votes:

Election of Mr. Yanlin Han, Dr. Alexander Wick, Ms Xuemei Liu, Mr. Zhanguo Weng, and Dr. Yiu Kwong Sun as the directors;
Amendment to Certificate of Incorporation to eliminate Article VII which states a specified number of directors;
Amendment to the By-laws of the Company to allow the Board of Directors to set the number of directors at a range from 1 to 11;
Adoption of 2005 Stock Option Plan.

“We are very pleased to see the support of our shareholders on all proposals” said by Yanlin Han, Chairman and CEO of the Company, “The amendments to our by-laws and Certificate of Incorporation will allow us to expand our board and appoint additional directors. We intend to appoint additional independent board members to meet the American Stock Exchange (AMEX) listing standard, which requires a majority of the Board to be independent directors. In addition, we intend to establish an audit committee and a compensation committee consisting of solely independent directors. The Company is in the final stage of searching for appropriate individuals as the independent Board members who will bring along their valuable experience and creditability for the Company to move forward.

Find Dragon Pharma Steroids

Dragon Pharma has provided our customers the highest level of pharmacy services throughout the continuum of the overall healthcare system: Masteron 100.

No Tags

1724 total views, 1 today

Popular
Comments
Tags

Dragon Ships EPO Internationally

Dragon Pharmaceuticals Inc. (NASDAQ OTC: DRUG) today announced that it has filled orders for recombinant erythropoietin (EPO) from Egypt, India and Peru where, in addition to China, the Company’s EPO is approved for use in the treatment of anemia related to chronic renal failure. All dollar amounts are stated in US dollars. “Penetrating new markets […]
Dragon Pharmaceutical Inc. Announces 2002 Fourth Quarter and Full Year Results

Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced results for the three-month and twelve-month periods ending December 31, 2002. 2002 Highlights Generated revenues of $7.36 million, representing significant growth from $3.07 million in 2001. Enhancement of gross margin in 2002 to 86.7% from 81% in 2001. Reported a first ever operating profit of […]
Dragon Announces Participation at Biopartnering Europe 2001

Dragon Pharmaceuticals Inc. (OTC BB – DRUG.OB) is pleased to announce that it has been invited to present at the BioPartnering Europe 2001 conference to be held at the Queen Elizabeth II Conference Centre in London, England from October 14th to 16th, 2001. BioPartnering Europe is the premier European venue for showcasing innovative biopharmaceutical and […]
Dragon Launches EPO Into the Brazilian Market

Dragon Pharmaceuticals Inc. (OTC BB: DRUG; TSX: DDD) today announced that it has shipped an order of recombinant erythropoietin (“EPO? to Itaca Laboratorios Ltda., (“Itaca” of Brazil. Itaca, a distribution partner of the company, has won a 3.1 million Brazilian Real tender for Dragon’s EPO in the Brazilian state of Minas, Gerais, which converts to […]
Dragon Signs Licensing Agreement for Korea

Dragon Pharmaceuticals Inc. (OTCBB – DRUG.OB) today announced that it has entered into a marketing and licensing agreement with Boryung Biopharma Company, Ltd. of Seoul, Korea for the distribution of recombinant Erythropoietin (EPO) in North and South Korea. According to the agreement, Boryung Biopharma will also be responsible for obtaining marketing for EPO from the […]